Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors

Aiko Suminoe, Akinobu Matsuzaki, Hiroyoshi Hattori, Yuhki Koga, Toshiro Hara

研究成果: ジャーナルへの寄稿記事

35 引用 (Scopus)

抄録

Immature DCs were generated from the peripheral blood monocytes from five children with refractory solid tumors (Ewing sarcoma, synovial sarcoma, neuroblastoma) using GM-CSF and IL-4. These DCs were then pulsed with tumor-specific synthetic peptides or tumor lysates in the presence of the immunogenic protein KLH for 12 h. Pulsed DCs were administered subcutaneously every one or two weeks in an outpatient setting without any toxicity. In one patient with Ewing sarcoma, the residual tumor disappeared following autologous PBSCT and DC therapy, and a complete remission has been maintained for 77 months. In two patients with synovial sarcoma or with neuroblastoma, growth of the tumors was temporally suppressed for one and 10 months, respectively, followed by their exacerbation. A DTH response was detected against KLH in all five patients and against the tumor lysate in one patient. In the patients with a possible DC-mediated anti-tumor effect, the number of CD8+ HLA-DR+ lymphocytes and INF-γ+CD8+ lymphocytes increased and an elevation of the NK cell cytotoxic activity was observed during and/or after DC therapy. DC-based immunotherapy may therefore be a feasible, well-tolerated and promising approach in the treatment of children with refractory malignant tumors.

元の言語英語
ページ(範囲)746-753
ページ数8
ジャーナルPediatric Transplantation
13
発行部数6
DOI
出版物ステータス出版済み - 9 1 2009

Fingerprint

Neoplasm Antigens
Immunotherapy
Dendritic Cells
Neoplasms
Synovial Sarcoma
Ewing's Sarcoma
Neuroblastoma
Lymphocytes
Residual Neoplasm
HLA-DR Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
Natural Killer Cells
Interleukin-4
Monocytes
Outpatients
Therapeutics
Peptides
Growth
Proteins

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

これを引用

Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. / Suminoe, Aiko; Matsuzaki, Akinobu; Hattori, Hiroyoshi; Koga, Yuhki; Hara, Toshiro.

:: Pediatric Transplantation, 巻 13, 番号 6, 01.09.2009, p. 746-753.

研究成果: ジャーナルへの寄稿記事

Suminoe, Aiko ; Matsuzaki, Akinobu ; Hattori, Hiroyoshi ; Koga, Yuhki ; Hara, Toshiro. / Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. :: Pediatric Transplantation. 2009 ; 巻 13, 番号 6. pp. 746-753.
@article{bcc790580ba54012aeac04d2efe5a55c,
title = "Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors",
abstract = "Immature DCs were generated from the peripheral blood monocytes from five children with refractory solid tumors (Ewing sarcoma, synovial sarcoma, neuroblastoma) using GM-CSF and IL-4. These DCs were then pulsed with tumor-specific synthetic peptides or tumor lysates in the presence of the immunogenic protein KLH for 12 h. Pulsed DCs were administered subcutaneously every one or two weeks in an outpatient setting without any toxicity. In one patient with Ewing sarcoma, the residual tumor disappeared following autologous PBSCT and DC therapy, and a complete remission has been maintained for 77 months. In two patients with synovial sarcoma or with neuroblastoma, growth of the tumors was temporally suppressed for one and 10 months, respectively, followed by their exacerbation. A DTH response was detected against KLH in all five patients and against the tumor lysate in one patient. In the patients with a possible DC-mediated anti-tumor effect, the number of CD8+ HLA-DR+ lymphocytes and INF-γ+CD8+ lymphocytes increased and an elevation of the NK cell cytotoxic activity was observed during and/or after DC therapy. DC-based immunotherapy may therefore be a feasible, well-tolerated and promising approach in the treatment of children with refractory malignant tumors.",
author = "Aiko Suminoe and Akinobu Matsuzaki and Hiroyoshi Hattori and Yuhki Koga and Toshiro Hara",
year = "2009",
month = "9",
day = "1",
doi = "10.1111/j.1399-3046.2008.01066.x",
language = "English",
volume = "13",
pages = "746--753",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors

AU - Suminoe, Aiko

AU - Matsuzaki, Akinobu

AU - Hattori, Hiroyoshi

AU - Koga, Yuhki

AU - Hara, Toshiro

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Immature DCs were generated from the peripheral blood monocytes from five children with refractory solid tumors (Ewing sarcoma, synovial sarcoma, neuroblastoma) using GM-CSF and IL-4. These DCs were then pulsed with tumor-specific synthetic peptides or tumor lysates in the presence of the immunogenic protein KLH for 12 h. Pulsed DCs were administered subcutaneously every one or two weeks in an outpatient setting without any toxicity. In one patient with Ewing sarcoma, the residual tumor disappeared following autologous PBSCT and DC therapy, and a complete remission has been maintained for 77 months. In two patients with synovial sarcoma or with neuroblastoma, growth of the tumors was temporally suppressed for one and 10 months, respectively, followed by their exacerbation. A DTH response was detected against KLH in all five patients and against the tumor lysate in one patient. In the patients with a possible DC-mediated anti-tumor effect, the number of CD8+ HLA-DR+ lymphocytes and INF-γ+CD8+ lymphocytes increased and an elevation of the NK cell cytotoxic activity was observed during and/or after DC therapy. DC-based immunotherapy may therefore be a feasible, well-tolerated and promising approach in the treatment of children with refractory malignant tumors.

AB - Immature DCs were generated from the peripheral blood monocytes from five children with refractory solid tumors (Ewing sarcoma, synovial sarcoma, neuroblastoma) using GM-CSF and IL-4. These DCs were then pulsed with tumor-specific synthetic peptides or tumor lysates in the presence of the immunogenic protein KLH for 12 h. Pulsed DCs were administered subcutaneously every one or two weeks in an outpatient setting without any toxicity. In one patient with Ewing sarcoma, the residual tumor disappeared following autologous PBSCT and DC therapy, and a complete remission has been maintained for 77 months. In two patients with synovial sarcoma or with neuroblastoma, growth of the tumors was temporally suppressed for one and 10 months, respectively, followed by their exacerbation. A DTH response was detected against KLH in all five patients and against the tumor lysate in one patient. In the patients with a possible DC-mediated anti-tumor effect, the number of CD8+ HLA-DR+ lymphocytes and INF-γ+CD8+ lymphocytes increased and an elevation of the NK cell cytotoxic activity was observed during and/or after DC therapy. DC-based immunotherapy may therefore be a feasible, well-tolerated and promising approach in the treatment of children with refractory malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=68849107068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849107068&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2008.01066.x

DO - 10.1111/j.1399-3046.2008.01066.x

M3 - Article

C2 - 19067917

AN - SCOPUS:68849107068

VL - 13

SP - 746

EP - 753

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

ER -